Abstract
Background: Zinc oxide nanoparticle (ZNP) has been applied in various biomedical fields. Here, we investigated the usage of ZNP as an antigen carrier for vaccine development by combining a high affinity peptide to ZNP. Results: A novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a =2.26×106M1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus. The ZNP/ZBP-ScaA complex was efficiently phagocytosed by a dendritic cell line, DC2.4, in vitro and significantly enhanced anti-ScaA antibody responses in vivo compared to control groups. In addition, immunization with the ZNP/ZBP-ScaA complex promoted the generation of IFN-γ-secreting T cells in an antigen-dependent manner. Finally, we observed that ZNP/ZBP-ScaA immunization provided protective immunity against lethal challenge of O. tsutsugamushi, indicating that ZNP can be used as a potent adjuvant when complexed with ZBP-conjugated antigen. Conclusions: ZNPs possess good adjuvant potential as a vaccine carrier when combined with an antigen having a high affinity to ZNP. When complexed with ZBP-ScaA antigen, ZNPs could induce strong antibody responses as well as protective immunity against lethal challenges of O. tsutsugamushi. Therefore, application of ZNPs combined with a specific soluble antigen could be a promising strategy as a novel vaccine carrier system.
| Original language | English |
|---|---|
| Article number | 76 |
| Journal | Journal of Nanobiotechnology |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 Nov 26 |
Fingerprint
Keywords
- Scrub typhus
- Vaccine
- Zinc oxide nanoparticle
- ZnO binding peptide
ASJC Scopus subject areas
- Bioengineering
- Medicine (miscellaneous)
- Molecular Medicine
- Biomedical Engineering
- Applied Microbiology and Biotechnology
- Pharmaceutical Science
Cite this
Generation of protective immunity against Orientia tsutsugamushi infection by immunization with a zinc oxide nanoparticle combined with ScaA antigen. / Ha, Na Young; Shin, Hyun Mu; Sharma, Prashant; Cho, Hyun Ah; Min, Chan Ki; Kim, Hong il; Yen, Nguyen Thi Hai; Kang, Jae Seung; Kim, Ik Sang; Choi, Myung Sik; Kim, Young-geun; Cho, Nam Hyuk.
In: Journal of Nanobiotechnology, Vol. 14, No. 1, 76, 26.11.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Generation of protective immunity against Orientia tsutsugamushi infection by immunization with a zinc oxide nanoparticle combined with ScaA antigen
AU - Ha, Na Young
AU - Shin, Hyun Mu
AU - Sharma, Prashant
AU - Cho, Hyun Ah
AU - Min, Chan Ki
AU - Kim, Hong il
AU - Yen, Nguyen Thi Hai
AU - Kang, Jae Seung
AU - Kim, Ik Sang
AU - Choi, Myung Sik
AU - Kim, Young-geun
AU - Cho, Nam Hyuk
PY - 2016/11/26
Y1 - 2016/11/26
N2 - Background: Zinc oxide nanoparticle (ZNP) has been applied in various biomedical fields. Here, we investigated the usage of ZNP as an antigen carrier for vaccine development by combining a high affinity peptide to ZNP. Results: A novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a =2.26×106M1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus. The ZNP/ZBP-ScaA complex was efficiently phagocytosed by a dendritic cell line, DC2.4, in vitro and significantly enhanced anti-ScaA antibody responses in vivo compared to control groups. In addition, immunization with the ZNP/ZBP-ScaA complex promoted the generation of IFN-γ-secreting T cells in an antigen-dependent manner. Finally, we observed that ZNP/ZBP-ScaA immunization provided protective immunity against lethal challenge of O. tsutsugamushi, indicating that ZNP can be used as a potent adjuvant when complexed with ZBP-conjugated antigen. Conclusions: ZNPs possess good adjuvant potential as a vaccine carrier when combined with an antigen having a high affinity to ZNP. When complexed with ZBP-ScaA antigen, ZNPs could induce strong antibody responses as well as protective immunity against lethal challenges of O. tsutsugamushi. Therefore, application of ZNPs combined with a specific soluble antigen could be a promising strategy as a novel vaccine carrier system.
AB - Background: Zinc oxide nanoparticle (ZNP) has been applied in various biomedical fields. Here, we investigated the usage of ZNP as an antigen carrier for vaccine development by combining a high affinity peptide to ZNP. Results: A novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a =2.26×106M1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus. The ZNP/ZBP-ScaA complex was efficiently phagocytosed by a dendritic cell line, DC2.4, in vitro and significantly enhanced anti-ScaA antibody responses in vivo compared to control groups. In addition, immunization with the ZNP/ZBP-ScaA complex promoted the generation of IFN-γ-secreting T cells in an antigen-dependent manner. Finally, we observed that ZNP/ZBP-ScaA immunization provided protective immunity against lethal challenge of O. tsutsugamushi, indicating that ZNP can be used as a potent adjuvant when complexed with ZBP-conjugated antigen. Conclusions: ZNPs possess good adjuvant potential as a vaccine carrier when combined with an antigen having a high affinity to ZNP. When complexed with ZBP-ScaA antigen, ZNPs could induce strong antibody responses as well as protective immunity against lethal challenges of O. tsutsugamushi. Therefore, application of ZNPs combined with a specific soluble antigen could be a promising strategy as a novel vaccine carrier system.
KW - Scrub typhus
KW - Vaccine
KW - Zinc oxide nanoparticle
KW - ZnO binding peptide
UR - http://www.scopus.com/inward/record.url?scp=85005978160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85005978160&partnerID=8YFLogxK
U2 - 10.1186/s12951-016-0229-2
DO - 10.1186/s12951-016-0229-2
M3 - Article
VL - 14
JO - Journal of Nanobiotechnology
JF - Journal of Nanobiotechnology
SN - 1477-3155
IS - 1
M1 - 76
ER -